Wacker Biotech GmbH
Halle, Germany
In the science hub of Halle, Germany, Wacker Biotech develops and produces biologics for international pharmaceutical and biotechnology companies. Since 2024, our new competence center here has been producing therapeutic proteins and mRNA-based actives. Production is based on stable, highly efficient processes and technologies to ensure high-quality yet cost-effective work. The company’s years of experience in developing biopharmaceuticals means that customers receive tailor-made solutions to meet their unique needs. Wacker Biotech works closely with customers and partners in order to best fulfill their requirements and achieve success together.
Full-Service Provider for the Microbial Production of Pharmaceutical Proteins
Customized Vaccine Development at Our mRNA Technical Center
Wacker Biotech GmbH is a leading producer of biopharmaceuticals. Headquartered in Jena, it operates a site in Halle (Saale), which has over 20 years of experience in the industry. This is where Wacker Biotech develops and produces therapeutic proteins and mRNA-based active ingredients/LNP formulations. Halle is considered one of Europe’s leading life sciences hubs.
In addition to medium-sized companies, the audited multi-purpose plant also supplies internationally active pharmaceutical and biotechnology companies. Its service portfolio includes the expression of target proteins in soluble form (ESETEC®) and a protein refolding (FOLDTEC®) method for manufacturing proteins that cannot be produced in their active form in bacterial cells. What’s more, the site offers the fermentation-generated production of pDNA based on our proprietary PLASMITEC® platform. pDNA is used as an important starting material for advanced therapies such as viral vectors and mRNA.
Its combination of innovation, quality and efficiency has established Wacker Biotech as a reliable partner for the biopharmaceuticals industry. Opened in 2024, the new mRNA competence center focuses on the production of active ingredients and vaccines for various disease indications. Our expertise in this field was honored with the award of a pandemic readiness contract for mRNA vaccines by the German government. WACKER is proud to do its part in making sure patients throughout the world have access to life-saving medicines. Another of our aims is to produce, on behalf of global pharmaceutical partners, mRNA active-ingredient solutions used, for example, in cancer treatment.
Jobs & Careers
Employees on campus have access to two cafeterias, a JobRad bicycle leasing program and good connections to public transit. Our interdepartmental projects promote equal opportunity, teamwork and camaraderie. A committed, on-site employee council protects and represents the interests of employees. Welcome to the WACKER team!
Site-Specific Facts & Figures
- Name: Wacker Biotech GmbH
- Site: Halle
- Employees: approx. 250
- Products: recombinant proteins (contract manufacturing), pharmaceutical actives for clinical testing and for the commercial market, mRNA drug product intermediates manufacturing (starting in 2024)
- The facility is certified in accordance with Good Manufacturing Practice (GMP) and complies with the requirements stipulated by the European and US drug-approval authorities (EMA and FDA, respectively)
